Profil
Sharon Elkobi worked as Vice President-Business Development at Neurim Pharmaceuticals Ltd.
and Chemomab Therapeutics Ltd.
from 2019 to 2022.
She holds a graduate degree and an MBA from Tel-Aviv University.
Anciens postes connus de Sharon Elkobi
| Sociétés | Poste | Fin |
|---|---|---|
| CHEMOMAB THERAPEUTICS LTD. | Investor Relations Contact | - |
Neurim Pharmaceuticals Ltd.
 Neurim Pharmaceuticals Ltd. BiotechnologyHealth Technology Neurim Pharmaceuticals Ltd. is a neuroscience drug discovery and development company. The company provides Circadin, a prolonged release melatonin for insomnia. Its products include orlogin, for circadian rhythm disorders; Neu-120, which has been developed as adjunct therapy to levodopa in patients with motor fluctuations; Neu-P11, a melatonin agonist binds with high affinity to melatonin receptors; and Neu-105 for the treatment of asthma. The company was founded in 1991 by Nava Zisapel and Yehuda Zisapel and is headquartered in Tel-Aviv, Israel. | Corporate Officer/Principal | - |
Formation de Sharon Elkobi
| Tel-Aviv University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CHEMOMAB THERAPEUTICS LTD. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Neurim Pharmaceuticals Ltd.
Neurim Pharmaceuticals Ltd. BiotechnologyHealth Technology Neurim Pharmaceuticals Ltd. is a neuroscience drug discovery and development company. The company provides Circadin, a prolonged release melatonin for insomnia. Its products include orlogin, for circadian rhythm disorders; Neu-120, which has been developed as adjunct therapy to levodopa in patients with motor fluctuations; Neu-P11, a melatonin agonist binds with high affinity to melatonin receptors; and Neu-105 for the treatment of asthma. The company was founded in 1991 by Nava Zisapel and Yehuda Zisapel and is headquartered in Tel-Aviv, Israel. | Health Technology |
